Results 21 to 30 of about 4,291 (203)

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients

Frontiers in Immunology, 2022
The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease.
Antti Nätynki, Päivi Leisti, Jussi Tuusa, Outi Varpuluoma, Laura Huilaja, Kentaro Izumi, Sanna-Kaisa Herukka, Olavi Ukkola, Juhani Junttila, Nina Kokkonen, Kaisa Tasanen   +10 more
doaj   +1 more source

BP230- and BP180-specific Auto-Antibodies in Bullous Pemphigoid [PDF]

Journal of Investigative Dermatology, 2004
Bullous pemphigoid is a subepidermal blistering disease associated with auto-antibodies (auto-ab) to BP180 and BP230. We developed ELISAs utilizing baculovirus-encoded recombinant proteins of BP230 and BP180 and studied their diagnostic and prognostic values by assessing the profile of the auto-ab response in 127 patients with BP. 39 patients had focal
Thoma-Uszynski, Sybille, Uter, Wolfgang, Schwietzke, Susanne, Hofmann, Silke, Hunziker, Thomas, Bernard, Philippe, Treudler, Regina, Zouboulis, Christos C., Schuler, Gerold, Borradori, Luca, Hertl, Michael   +10 more
openaire   +3 more sources

A Specific Signature of Circulating Free Fatty Acid Discriminates Bullous Pemphigoid From Pemphigus Vulgaris and Healthy Controls. [PDF]

Exp Dermatol
ABSTRACT Bullous pemphigoid (BP) is an autoimmune skin disorder marked by antibodies targeting basement membrane proteins BP180 and BP230. Recent evidence suggests a role for the gut–skin axis and microbial metabolites, especially short‐chain fatty acids (SCFAs), in modulating skin homeostasis and immune responses.
Baldi S, Bertorello S, Cei F, Nannini G, Menicatti M, Niccolai E, Bartolucci G, Baffa ME, Pipitò C, Antiga E, Amedei A, Maglie R.   +11 more
europepmc   +2 more sources

Autoantibodies Against the Immunodominant Bullous Pemphigoid Epitopes Are Rare in Patients With Dermatitis Herpetiformis and Coeliac Disease

Frontiers in Immunology, 2020
Dermatitis herpetiformis (DH) is an extraintestinal manifestation of coeliac disease (CD). Patients with DH have an elevated risk of development of another autoimmune blistering skin disease, bullous pemphigoid (BP). In this study we investigated whether
Antti Nätynki, Jussi Tuusa, Kaisa Hervonen, Kaisa Hervonen, Katri Kaukinen, Katri Kaukinen, Outi Lindgren, Outi Lindgren, Laura Huilaja, Nina Kokkonen, Teea Salmi, Teea Salmi, Kaisa Tasanen   +12 more
doaj   +1 more source

Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis

Frontiers in Medicine, 2022
BackgroundBullous pemphigoid (BP) is the most common autoimmune-blistering disease, clinically characterized by erythematous urticarial plaques, blisters, and intense pruritus, induced by autoantibodies against two proteins of the dermo-epidermal ...
Francesco Moro, Francesco Moro, Feliciana Mariotti, Anna Pira, Naomi De Luca, Biagio Didona, Gianluca Pagnanelli, Giovanni Di Zenzo   +7 more
doaj   +1 more source

How Does Intramolecular Epitope Spreading Occur in BPAG2 (BP180)? [PDF]

Journal of Investigative Dermatology, 2010
Several studies have suggested that autoantibodies directed against multiple epitopes occur via epitope spreading in autoimmune bullous skin diseases. However, the precise sequence of events in epitope spreading has not been elucidated for any of the epidermal autoantigens. In this issue, using a transgenic mouse model, Di Zenzo et al.
Hashimoto, Takashi, Hamada, Takahiro, Dainichi, Teruki, Ishii, Norito, Karashima, Tadashi, Nakama, Takekuni, Yasumoto, Shinichiro   +6 more
openaire   +2 more sources

IgE autoantibodies and their association with the disease activity and phenotype in Bullous Pemphigoid: a systematic review [PDF]

, 2017
Bullous Pemphigoid (BP) is the most common autoimmune skin disease of blistering character. The underlying pathophysiological mechanism involves an immune attack, usually by IgG class autoantibodies, on the autoantigen BP 180/BPAg2, which is a type XVII ...
Fairclough, Lucy C., Hadjikyriacou Saniklidou, Ariadne, Tighe, Patrick J., Todd, Ian   +3 more
core   +2 more sources

A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors

Frontiers in Immunology, 2019
Background: Anti-hyperglycemic drug dipeptidyl peptidase-IV inhibitors (DPP-4i) have recently been recognized as bullous pemphigoid (BP) inducing drugs. It remains uncertain whether DPP-4i induce BP-IgG autoantibodies before the onset of BP.Objective: To
Kentaro Izumi, Wataru Nishie, Mutsuo Beniko, Hiroshi Shimizu   +3 more
doaj   +1 more source

A role for anti‐BP180 autoantibodies in chronic rhinosinusitis [PDF]

The Laryngoscope, 2013
Objectives/HypothesisChronic Rhinosinusitis (CRS) is accompanied by evidence of a vigorous adaptive immune response, and emerging studies demonstrate that some nasal polyps manifest a polyclonal autoantibody response. We previously found that antibodies against BP180, a component of the hemidesmosome complex and the dominant epitope in autoimmune ...
Jill S, Jeffe, Sudarshan, Seshadri, Kevin J, Hamill, Julia He, Huang, Roderick, Carter, Lydia, Suh, Kathryn E, Hulse, James, Norton, David B, Conley, Rakesh K, Chandra, Robert C, Kern, Jonathan C R, Jones, Robert P, Schleimer, Bruce K, Tan   +13 more
openaire   +2 more sources

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180

Frontiers in Immunology, 2019
Bullous pemphigoid (BP) is a common autoimmune blistering disease in which autoantibodies target the hemidesmosomal components BP180 and/or BP230 in basal keratinocytes.
Yosuke Mai, Wataru Nishie, Kentaro Izumi, Hiroshi Shimizu   +3 more
doaj   +1 more source